AbbVie Inc. $ABBV Shares Bought by Global X Japan Co. Ltd.

Global X Japan Co. Ltd. increased its position in AbbVie Inc. (NYSE:ABBV) by 587.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 25,664 shares of the company’s stock after purchasing an additional 21,932 shares during the period. AbbVie accounts for about 0.5% of Global X Japan Co. Ltd.’s holdings, making the stock its 27th biggest holding. Global X Japan Co. Ltd.’s holdings in AbbVie were worth $5,942,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ABBV. Ellenbecker Investment Group lifted its stake in AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA increased its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after acquiring an additional 45 shares during the period. Matthew Goff Investment Advisor LLC raised its position in AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after purchasing an additional 45 shares during the last quarter. Hobart Private Capital LLC boosted its stake in AbbVie by 4.4% during the 3rd quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock worth $261,000 after purchasing an additional 48 shares during the period. Finally, Rise Advisors LLC boosted its stake in AbbVie by 3.4% during the 3rd quarter. Rise Advisors LLC now owns 1,451 shares of the company’s stock worth $336,000 after purchasing an additional 48 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. UBS Group increased their price objective on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Wells Fargo & Company boosted their target price on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Guggenheim upped their price target on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Finally, Evercore ISI increased their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $245.84.

AbbVie Trading Up 0.6%

Shares of ABBV stock opened at $230.18 on Thursday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock has a market cap of $406.81 billion, a P/E ratio of 174.38, a P/E/G ratio of 1.30 and a beta of 0.36. The business has a fifty day simple moving average of $226.65 and a 200-day simple moving average of $212.00. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the prior year, the company earned $3.00 EPS. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.